1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US10336719B2
公开(公告)日:2019-07-02
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
本发明涉及 1-(3-磺酰基苯基)-3-(环戊-2-烯-1-基)脲衍生物及其在治疗或预防由 CXCR2 受体介导的疾病和病症中的用途。此外,本发明还涉及含有这些衍生物的组合物及其制备工艺。